期刊文献+

乳腺癌HER2/neu手性多肽疫苗的实验研究

Experimental study of HER2/neu chiral polypeptide vaccine of breast cancer
下载PDF
导出
摘要 目的研究具有局部手性的HER-2/neu多肽疫苗对细胞毒性T细胞(CTLs)的诱导作用。方法用固相法合成HER-2/neu手性肽疫苗并进行纯化,建立小鼠的乳腺癌模型,用上述手性肽做疫苗、重组人粒细胞-巨噬细胞集落刺激因子(GM-CSF)为佐剂,对小鼠进行免疫,分别应用MTT法、ELISPOT法、颗粒酶释放法测定T细胞的增殖,T细胞分泌IFN-γ,CTL对肿瘤细胞的杀伤活性。结果合成的手性HER-2/neu可明显的促进T细胞增殖,促进T细胞分泌IFN-γ及诱导CTL杀伤乳腺癌细胞。结论手性HER-2/neu多肽疫苗可在小鼠体内诱导特异细胞免疫,增加对乳腺癌细胞的杀伤作用。 Objective To study the induction of HER-2/neu specific CTLs in mice by partial chiral peptide vaccine. Methods The HER-2/neu chiral peptide was synthesized using solid phase peptide synthesis method and purified. Breast cancer model of BALB/c mice was constructed, HER-2/neu chiral peptides were used as vaccine, GM-CSF was used as adjuvant to activate cell immunity. MTT, ELISPOT and relapse method of granule enzyme were adopted respectively to test the proliferation of the T cells , IFN-γ secretion by T cells and the ability of CTLs to kill the cancer cells. Results Cell immunity was stimulated by chiral HER-2/neu peptide vaccine including T cells proliferation, the incremental secretion of IFN-γ by T cells, activation of CTLs to kill breast cancer cell. Conclusions The chiral HER-2/neu peptide vaccine could induce HER-2/neu specific CTLs in mice, activate cell immunity, enhance the ability to kill breast cancer cell.
出处 《中国老年学杂志》 CAS CSCD 北大核心 2008年第14期1367-1369,共3页 Chinese Journal of Gerontology
基金 国家自然科学基金资助(30600743)
关键词 乳腺癌 手性 疫苗 HER-2/NEU 细胞毒性T细胞(CTLs) Breast cancer Chiral Vaccine HER-2/neu Cytotoxic T lymphocytes (CTL) s
  • 相关文献

参考文献11

  • 1Schlegel J, Ullrich B, Stumm G, et al. Expression of the c-erbB-2-encoded oneoprotein and progesterone receptor in human meningiomas [ J ]. J Immunol,1997;159( 11 ) :5509-15. 被引量:1
  • 2Goodell V,Waisman J,Salazar LG,et al. Level of HER-2/neu protein expression in breast cancer may affect the development of endogenous HER- 2/neu-specific immunity[ J]. Mol Cancer Ther,2008 ;7 ( 3 ) :449-54. 被引量:1
  • 3Reddish M,MacLean GD,Koganty RR,et al. Anti-MUC-1 class Ⅰ restricted CTLs in metastic breast cancer patients immunized with a synthetic MUC1 peptide[J]. Int J Cancer,1998;76(6) :817-23. 被引量:1
  • 4Disis ML, Kelmith H, Grabstein, et al. Generation of immunity to the HER-2/neu oneogenie protein in patients with breast and ovarian cancer using a peptide-based vaccine[ J]. Clin Cancer Res, 1999 ;5 : 1289-97. 被引量:1
  • 5柳忠辉,吕昌龙主编..免疫学常用实验技术[M].北京:科学出版社,2002:143.
  • 6Knutson KL,Schiffman K, Disis ML,et al. Immunization with a HER-2/ neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients[ J]. J Clin Invest ,2001 ; 107:477-84. 被引量:1
  • 7沈关心,周汝麟主编..现代免疫学实验技术[M].武汉:湖北科学技术出版社,1998:510.
  • 8Nagorsen D,Keilholz U,Rivoltini L,et al. Natural T-cell response against MHC class I epitopes of epithelial cell adhesion molecule, HER-2/neu, and carcinoembryonic antigen in patienta with colorectal cancer [J]. Cancer Res,2000 ;60:4850-4. 被引量:1
  • 9Fauchere JL,Thurieau C. Evaluation of the stability of peptides and pseudopeptides as a tool in peptide drug design [ J ]. Adv Drug Res, 1992 ;23: 127-59. 被引量:1
  • 10Geysen HM, Rodda SJ, Mason TJ. A priori delineation of a pepfide which mimics a scontinuous antigenic determinant [ J ]. Mol Immunol, 1986 ;23 (7) :709-15. 被引量:1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部